Business
InvestmentPitch Media Video Discusses Willow Biosciences' Cannabinoid Scale-Up and Expedited Path to Commercialization - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2020) - Willow Biosciences (TSX: WLLW...
About this update from Atlas Energy Corp.
[{"type":"text","content":"InvestmentPitch Media Video Discusses Willow Biosciences' Cannabinoid Scale-Up and Expedited Path to Commercialization - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - March 13, 2020) - Willow Biosciences (TSX: WLLW) (OTCQB: CANSF) has achieved its first major commercial milestone by delivering a proprietary cannabinoid-producing yeast strain to its scale-up development partner, Albany Molecular Research, Inc. (\"AMRI\") to begin the process of scaling up production to commercial volumes. AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life.For more information, please view the InvestmentPitch Media \"video\" which provides additional information on the company and this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Willow\" in the search box. Cannot view this video? Visit:http://www.investmentpitch.com/With locations in North America, Europe and Asia, AMRI's team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product.Calgary-based Willow, a Canadian biotechnology company, produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow's manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs. Willow's successful yeast-strain engineering efforts have created multiple cannabinoid strains with promising properties that the company will use as a basis for commercialization. The company's skilled science team were able to reach this critical step ahead of its initial expectations and combined with its partnership with AMRI, the Company expects to reach its commercialization phase in the first half of 2021, six months sooner than originally expected.Trevor Peters, CEO, stated: \"We are extremely pleased with the success of our scientists. Their ability to create the yeast strain that will form the base of our future production ahead of expectations, is a testament to their skill and expertise. As we move into...